Business

Cartherics and Zucker Institute execute research collaboration and option agreement to combine iPSC-derived NK cell platform with novel anti-tissue factor antibody

Melbourne, Australia –   Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced that it has executed…

Read more